169 -2 (88) 2026 - Artikova S.G., Isakova D.Z. - ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE

Artikova S.G. - Andijan State Medical Institute

Isakova D.Z. - Andijan State Medical Institute

Valieva Z.S. - Andijan State Medical Institute

Yunusova Z.V. - Andijan State Medical Institute

Resume

This article addresses contemporary approaches to the assessment of cardiometabolic risk in patients with metabolically associated fatty liver disease (MAFLD). MAFLD is closely linked to insulin resistance, dyslipidemia, arterial hypertension, and type 2 diabetes mellitus, significantly increasing the risk of cardiovascular complications. An algorithm for comprehensive cardiometabolic risk assessment is proposed, based on the integrated analysis of clinical and anamnestic data, anthropometric parameters, and laboratory and instrumental findings. The application of this algorithm enables effective risk stratification, early identification of high-risk patients, and the development of individualized preventive and therapeutic strategies. The findings of this study may be useful for clinical practice and contribute to reducing cardiovascular morbidity in patients with MAFLD.

Keywords: metabolically associated fatty liver disease, cardiometabolic risk, insulin resistance, metabolic syndrome, cardiovascular diseases, risk assessment algorithm, dyslipidemia.

First page

917

Last page

923

For citation:Artikova S.G., Isakova D.Z., Valieva Z.S., Yunusova Z.V. - ALGORITHM FOR ASSESSING CARDIOMETABOLIC RISK IN PATIENTS WITH METABOLICALLY ASSOCIATED FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 917-923 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi:10.1038/nrgastro.2013.41
  2. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42(5):987–1000. doi:10.1002/hep.20920
  3. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1):47–64. doi:10.1016/j.jhep.2014.12.012
  4. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211–218. doi:10.1136/flgastro-2013-100403
  5. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
  6. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9
  7. Loomba R, Adams LA. Advances in NAFLD therapeutics. Nat Rev Gastroenterol Hepatol. 2020;17(1):11–13. doi:10.1038/s41575-019-0232-2
  8. Loomba R, Friedman SL, Shulman GI. Emerging mechanisms and potential therapeutics for NAFLD-related fibrosis. Hepatology. 2021;74(2):616–629. doi:10.1002/hep.31759
  9. Mantovani A, Byrne CD, Scorletti E, et al. Complications and outcomes of NAFLD and NASH. Nat Rev Gastroenterol Hepatol. 2021;18(4):257–267. doi:10.1038/s41575-020-00393-9
  10. Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147

    file

    download